Journal
Cancer Research
Publication Date
12-15-2023
Volume
83
Issue
24
First Page
4161
Last Page
4178
Document Type
Open Access Publication
DOI
10.1158/0008-5472.CAN-23-0604
Rights and Permissions
Wu Y, Chen S, Yang X, Sato K, Lal P, Wang Y, Shinkle AT, Wendl MC, Primeau TM, Zhao Y, Gould A, Sun H, Mudd JL, Hoog J, Mashl RJ, Wyczalkowski MA, Mo CK, Liu R, Herndon JM, Davies SR, Liu D, Ding X, Evrard YA, Welm BE, Lum D, Koh MY, Welm AL, Chuang JH, Moscow JA, Meric-Bernstam F, Govindan R, Li S, Hsieh J, Fields RC, Lim KH, Ma CX, Zhang H, Ding L, Chen F. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res. 2023 Dec 15;83(24):4161-4178. doi: 10.1158/0008-5472.CAN-23-0604. ©2023 The Authors; Published by the American Association for Cancer Research This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
Recommended Citation
Wu, Yige; Chen, Siqi; Yang, Xiaolu; Sato, Kazuhito; Lal, Preet; Shinkle, Andrew T; Wendl, Michael C; Primeau, Tina M; Zhao, Yanyan; Gould, Alanna; Sun, Hua; Mudd, Jacqueline L; Hoog, Jeremy; Mashl, R Jay; Wyczalkowski, Matthew A; Mo, Chia-Kuei; Liu, Ruiyang; Herndon, John M; Davies, Sherri R; Liu, Di; Ding, Xi; Govindan, Ramaswamy; Li, Shunqiang; Hsieh, James; Fields, Ryan C; Lim, Kian-Huat; Ma, Cynthia X; Ding, Li; Chen, Feng; and et al., "Combining the tyrosine kinase inhibitor cabozantinib and the mTORC1/2 inhibitor sapanisertib blocks ERK pathway activity and suppresses tumor growth in renal cell carcinoma." Cancer Research. 83, 24. 4161 - 4178. (2023).
https://digitalcommons.wustl.edu/oa_4/3122
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
